Adrian Gray
About Adrian Gray
Adrian Rawcliffe is the CEO with over 20 years of experience in the biopharmaceutical industry, having held several senior roles at GSK before becoming the Managing Partner and President of SR One Ltd.
Adrian Rawcliffe - Chief Executive Officer
Adrian Rawcliffe is the Chief Executive Officer. He has held this position since October 2019, bringing extensive experience in leadership and financial oversight to the role. Prior to this, Rawcliffe served as the Chief Financial Officer from March 2015 through September 2019, where he was instrumental in driving financial strategies and operations.
Adrian Rawcliffe's Education and Expertise
Adrian Rawcliffe boasts a robust educational background, holding a B.Sc. degree in Natural Sciences from the University of Durham, UK. Additionally, he qualified as a chartered accountant with PwC, which has underpinned his extensive career in finance and business development within the biopharmaceutical industry.
Adrian Rawcliffe's Industry Background
With over 20 years in the biopharmaceutical industry, Adrian Rawcliffe has developed a comprehensive understanding of the sector. He joined GSK in 1998 and held several senior roles, including Senior Vice President of Finance for GSK's North American Pharmaceuticals business. His experience also spans worldwide business development and R&D finance, focusing on business development and finance activities for GSK's Pharmaceuticals R&D business.
Adrian Rawcliffe's Contributions to GSK
Throughout his tenure at GSK, Adrian Rawcliffe held significant responsibilities, such as Senior Vice President Worldwide Business Development and R&D Finance. He played a key role in managing GSK's venture-capital business as Managing Partner and President of SR One Ltd, contributing to strategic investments and business growth.
Adrian Rawcliffe - Non-Executive Director at WAVE Life Sciences
In addition to his executive roles, Adrian Rawcliffe is currently serving as a non-executive director of WAVE Life Sciences. This position allows him to leverage his extensive experience in the biopharmaceutical industry to contribute to the strategic direction and governance of the company.